Clinical Trials Browser

Phase 1 × abiraterone × Genitourinary × Clear all

NCT04221542 2026-03-30

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

Bites and Stings, Prostatic Neoplasms

NCT07140900 2026-02-13

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms

NCT05276492 2025-10-03

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Phase 1 Terminated

Prostatic Neoplasms

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

Metastatic Castration-Resistant Prostate Cancer

NCT05177042 2025-07-25

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 Completed

Prostatic Neoplasms

NCT04291664 2024-10-17

PK and Dose Escalation and Expansion Study of DST-2970

Phase 1 Terminated

Prostatic Neoplasms

NCT04677855 2024-04-10

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Phase 1 Terminated

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04628988 2023-09-13

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT03569280 2023-07-18

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Phase 1 Completed

Prostatic Neoplasms

NCT04179396 2023-06-29

RAMP

Phase 1 Completed

8 enrolled 8 charts

Metastatic Castration Resistant Prostate Cancer

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1 Completed

Neoplasm Metastasis, Prostatic Neoplasms

NCT01574937 2021-08-06

XL-184+Abiraterone in Post-Chemo CRPC

Phase 1 Completed

Prostatic Neoplasms

NCT02883166 2020-12-07

SNACK

Phase 1 Completed

Prostatic Neoplasms

NCT01741753 2019-02-05

BKM120+Abiraterone Acetate for Metastatic CRPC

Phase 1 Terminated

Neoplasm Metastasis, Prostatic Neoplasms